Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer

A method of treating cancer in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a Type II protein arginine methyltransferase (Type II PRMT) inhibitor and administering to the human a therapeutically effective amount of an ICOS binding protein or antigen binding fragment thereof, wherein the Type II PRMT inhibitor is Compound C:

• or a pharmaceutically acceptable salt thereof, and the ICOS binding protein or antigen binding portion thereof comprises a VH domain comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO:7 and/or a VL domain comprising an amino acid sequence at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:8 wherein said ICOS binding protein specifically binds to human ICOS.

12-22. (canceled)

27-28. (canceled)